• Metoprolol: Selective Beta1-Adrenoceptor Antagonist for Rese

  2026-04-28

  Metoprolol is a selective beta1-adrenoceptor antagonist used extensively in cardiovascular disease research and in studies probing anti-inflammatory and anti-tumor mechanisms. Its well-defined pharmacological profile, rapid onset, and validated biochemical selectivity make it a cornerstone for mechanistic and translational studies in biomedical science.

• Bazedoxifene: Mechanistic Insights and Protocol Precision in

  2026-04-28

  Explore the unique mechanistic depth of Bazedoxifene as a selective estrogen receptor modulator for postmenopausal osteoporosis research. This article delivers protocol guidance and evidence-based assay design, setting it apart from typical SERM reviews.

• Losartan in Hypertension Research: Workflows and Innovations

  2026-04-27

  Losartan, a selective angiotensin II receptor antagonist, is instrumental in hypertension and cardiovascular physiology research, offering unique advantages in dissecting vascular and immune pathways. This article details optimized experimental workflows, data-driven protocol parameters, and troubleshooting insights—bridging foundational and translational research for next-generation therapeutic discovery.

• Berberine, SIRT6-AMPK Signaling, and NLRP3 in Atrial Fibrosi

  2026-04-27

  This article analyzes how berberine mitigates atrial fibrillation risk by inhibiting the NLRP3 inflammasome through upregulation of the SIRT6-AMPK pathway in angiotensin II-induced murine models. The findings provide mechanistic clarity for inflammation-driven atrial remodeling and suggest broader applications for metabolic and immunometabolic research.

• Transmission Dynamics of Carbapenemase Genes in CREC: Hospit

  2026-04-26

  This study systematically characterizes the prevalence and mobility of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) from eight hospitals in Guangdong, China during the COVID-19 pandemic. The findings highlight the predominance of plasmid-borne blaNDM-1, extensive multidrug resistance, and the rapid horizontal transfer potential of CEGs—crucial for infection control and antimicrobial stewardship.

• Doxorubicin Hydrochloride: Dual-Loaded Liposomes and Next-Ge

  2026-04-25

  Explore how Doxorubicin hydrochloride (Adriamycin HCl) is revolutionizing cancer chemotherapy research through dual-loaded liposome technology and advanced assay strategies. Gain actionable insights that go beyond conventional applications and leverage the latest encapsulation innovations.

• Scenario-Driven Solutions with Mubritinib (TAK 165, SKU B154

  2026-04-24

  This article guides biomedical researchers through common laboratory challenges in cell viability, proliferation, and cytotoxicity assays, using Mubritinib (TAK 165, SKU B1543) as a data-backed solution. Scenario-based Q&As highlight the compound's reliability, selectivity, and vendor advantages for robust AML and PEL research workflows.

• Deferasirox Pharmacokinetics and Clinical Evidence in Iron O

  2026-04-24

  This article reviews the pharmacokinetic profile and clinical outcomes of Deferasirox (Exjade) for iron overload management, based on a pivotal synthesis by Galanello et al. The findings clarify Deferasirox’s benefits, limitations, and research applications, offering practical context for preclinical and translational iron chelation studies.

• BODIPY 581/591 C11: Ratiometric Fluorescent Probe for Lipid

  2026-04-23

  BODIPY 581/591 C11 is a ratiometric fluorescent probe enabling quantitative detection of lipid peroxidation and oxidative stress in live cells. Its red-to-green emission shift upon oxidation by reactive oxygen species allows robust, reproducible measurement of membrane lipid damage and antioxidant capacity. This probe, supplied by APExBIO, is a benchmark tool in ferroptosis and redox biology research.

• Deferasirox Fe3+ Chelate: Applied Workflows for Iron Overloa

  2026-04-23

  Deferasirox Fe3+ chelate empowers translational research with high-purity, DMSO-soluble iron chelation for modeling beta-thalassemia and chronic anemia. This article delivers actionable protocols, troubleshooting strategies, and direct evidence for optimizing iron overload experiments in the laboratory.

• Fosinopril Sodium: Advanced ACE Inhibitor Workflows in Hyper

  2026-04-22

  Fosinopril sodium distinguishes itself as a phosphinic acid ACE inhibitor with dual renal-hepatic elimination, enabling precise modeling of blood pressure and renal hemodynamics. This article delivers actionable protocols, troubleshooting wisdom, and cross-study context for maximizing the translational value of APExBIO's Fosinopril sodium in cardiovascular and hypertension research.

• Azilsartan Medoxomil Monopotassium: Protocols for Hypertensi

  2026-04-22

  Azilsartan medoxomil monopotassium (TAK 491) sets a new benchmark for essential hypertension treatment research with unmatched potency and selectivity. Here we translate recent meta-analytical findings and real-world experimental workflows into actionable protocols, troubleshooting insights, and advanced use-cases to maximize the compound’s impact in cardiovascular disease research.

• Necrosulfonamide: Precision MLKL Inhibition in Necroptosis A

  2026-04-21

  Necrosulfonamide (NSA) delivers highly selective, nanomolar-range MLKL inhibition, uniquely empowering researchers to dissect necroptosis mechanisms in complex models. By integrating NSA into necroptosis assays, labs can achieve robust pathway dissection and reproducibility across cancer, neurodegeneration, and cardiovascular research.

• WZ4003 in Cell-Based Assays: Reliable NUAK1/2 Inhibition for

  2026-04-21

  This article addresses core laboratory challenges in cell viability and cytotoxicity assays by illustrating how WZ4003 (SKU B1374) delivers reproducible, specific NUAK1/2 inhibition. Drawing on peer-reviewed data and best-practice protocols, we compare WZ4003’s performance, selectivity, and application guidance, providing actionable insights for biomedical researchers and lab technicians. SKU B1374’s strengths in workflow compatibility, specificity, and translational relevance are highlighted.

• Losartan in Hypertension Research: Protocols and Optimizatio

  2026-04-20

  Losartan, a selective angiotensin II receptor antagonist, streamlines advanced hypertension and vascular biology research with robust reproducibility. This article delivers protocol enhancements, troubleshooting, and cross-study insights for maximizing Losartan's experimental value.

421 records 18/29 page Previous Next First page 上5页 1617181920 下5页 Last page